Health & Fitness
Thu, July 23, 2009Wed, July 22, 2009Tue, July 21, 2009Mon, July 20, 2009Sun, July 19, 2009Fri, July 17, 2009Thu, July 16, 2009Wed, July 15, 2009Tue, July 14, 2009Mon, July 13, 2009Fri, July 10, 2009Thu, July 9, 2009Wed, July 8, 2009Tue, July 7, 2009Mon, July 6, 2009Fri, July 3, 2009Thu, July 2, 2009Wed, July 1, 2009Tue, June 30, 2009Mon, June 29, 2009Fri, June 26, 2009Thu, June 25, 2009Wed, June 24, 2009Tue, June 23, 2009Mon, June 22, 2009Sun, June 21, 2009Fri, June 19, 2009Thu, June 18, 2009Wed, June 17, 2009Tue, June 16, 2009Mon, June 15, 2009Fri, June 12, 2009Thu, June 11, 2009Wed, June 10, 2009Tue, June 9, 2009Mon, June 8, 2009Sun, June 7, 2009Fri, June 5, 2009Thu, June 4, 2009Wed, June 3, 2009Tue, June 2, 2009Mon, June 1, 2009Sat, May 30, 2009Fri, May 29, 2009Thu, May 28, 2009Wed, May 27, 2009Tue, May 26, 2009Mon, May 25, 2009Fri, May 22, 2009Thu, May 21, 2009Wed, May 20, 2009Tue, May 19, 2009Mon, May 18, 2009Fri, May 15, 2009Thu, May 14, 2009Wed, May 13, 2009Pharming Group N.V.: Pharming announces Euro 9 million debt reduction and continued equity financing with Ya Global
Published in Health and Fitness on Tuesday, June 16th 2009 at 23:39 GMT, Last Modified on 2009-06-16 23:39:40 by Market Wire
LEIDEN, NETHERLANDS--(Marketwire - June 17, 2009) -
Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) announced today a further reduction of its outstanding amount of convertible debt and the further strengthening of its cash position under the agreement with YA Global Master SPV LTD ("YA Global").
Pharming entered into agreements with several bondholders to cancel EUR 9 million convertible bonds in exchange for issuance of 8 million ordinary shares. After completion of these transactions, the total outstanding amount of convertible debts is now reduced to EUR 35.8 million. In addition, Pharming issued about 1 million ordinary shares for a cash consideration of EUR 0.7 million under the Standby Equity Distribution Agreement with YA Global.
As a result of the above transactions, Pharming's total number of outstanding ordinary shares increased to approximately 109.5 million shares per today.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, intermediates for various applications and nutritional products. Pharming has two products in late stage development - Rhucin® for Hereditary Angioedema and human Lactoferrin for use in food products and one product in early stage clinical development - Prodarsan® for Cockayne Syndrome. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, [ http://www.pharming.com ].
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.
Contact:
Sijmen de Vries, Pharming Group NV, T: +31 (0)71 52 47 400
Press Release (PDF): [ http://hugin.info/132866/R/1323199/310436.pdf ]
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
